Press Release: October 7, 2024
Nader Gamini Joins Novelna Inc. as Chief Operating Officer
Palo Alto, California – – Novelna, a biotech company specializing in early cancer detection, is pleased to announce the appointment of Nader Gamini as its new Chief Operating Officer (COO). With nearly four decades of experience across the semiconductor and biotech industries, Nader’s expertise will play a critical role in accelerating Novelna’s product development and strengthening its position in the growing diagnostics market. His leadership will be pivotal in navigating industry complexities while driving the company toward sustained growth and innovation.
Nader Gamini – Chief Operating Officer
Nader Gamini’s distinguished career spans both startups and multi-billion-dollar public companies. He has led two successful IPOs and three acquisitions, in addition to serving on the board of directors for five companies. As COO and board member, he was instrumental in securing significant funding for two startups—Aeluros (acquired by NetLogic) and InSilixa (acquired by Danaher)—with investment from top-tier venture capital firms such as NEA, Morningside, and Hony Capital, as well as corporate investors like Danaher and Nvidia.
Nader has co-authored numerous papers in prestigious journals, including Nature Biotechnology, IEEE, and ECTC, where his contributions have advanced semiconductor technologies for molecular diagnostics, high-speed networking, and other key areas.
“We are thrilled to welcome Nader to the Novelna leadership team," said Ashkan Afshin, CEO of Novelna. "His extensive experience in both the semiconductor and biotech industries, along with his proven track record in leading companies through successful exits, will be invaluable as we push forward our mission to transform diagnostics and improve patient outcomes."
Nader’s appointment underscores Novelna’s commitment to building a world-class leadership team to advance its long-term vision. His extensive industry expertise and strategic leadership will be crucial in navigating the challenges of the diagnostics market and propelling Novelna to new heights of success.
For more information about Novelna and its advisory board, please visit www.novelna.com.
Contact Information: info@novelna.com
About Novelna Inc.: Novelna is a proteomics-based liquid biopsy startup, transforming cancer diagnostics. Our mission is simple: ensure early disease detection is not a privilege, but a right for all. By advancing diagnostic technologies, we are committed to securing a healthier and brighter future globally.